March 13, 2019 09:55 AM EDT
R&D

Cel­gene's chemother­a­py Abrax­ane stum­bles in piv­otal pan­cre­at­ic can­cer study

Natalie Grover

Reporter

Days af­ter Cel­gene’s Abrax­ane se­cured ap­proval in com­bi­na­tion with Roche’s check­point in­hibitor for front­line use in triple neg­a­tive breast can­cer, the US drug­mak­er re­port­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

A service from the Financial Times